doi: 10.1177/1352458509358939.
Corrigendum
- PMID: 20086030
- DOI: 10.1177/1352458509358939
Item in Clipboard
Corrigendum
Mult Scler.
2016 Oct.
Abstract
Corrigendum to 'Clinical vigilance for progressive multifocal leukoencephalopathy in the context of natalizumab use' by Carlo Tornatore and David B Clifford. Multiple Sclerosis 15(S4) S16-S25 [DOI: 10.1177/1352458509347130 ].
Similar articles
-
Multiple sclerosis, natalizumab therapy, and progressive multifocal leukoencephalopathy.Curr Opin Neurol. 2006 Aug;19(4):341-9. doi: 10.1097/01.wco.0000236612.66839.a2. Curr Opin Neurol. 2006. PMID: 16914971 Review.
-
Fingolimod to treat severe multiple sclerosis after natalizumab-associated progressive multifocal leukoencephalopathy: a valid option?Mult Scler. 2014 Apr;20(4):505-9. doi: 10.1177/1352458513516530. Epub 2013 Dec 23. Mult Scler. 2014. PMID: 24367037
-
Progressive multifocal leukoencephalopathy associated to natalizumab extended dosing regimen.Neurodegener Dis Manag. 2015 Oct;5(5):399-402. doi: 10.2217/nmt.15.42. Epub 2015 Oct 30. Neurodegener Dis Manag. 2015. PMID: 26517599
-
Immunological biomarkers identifying natalizumab-treated multiple sclerosis patients at risk of progressive multifocal leukoencephalopathy.J Neuroimmunol. 2014 Dec 15;277(1-2):6-12. doi: 10.1016/j.jneuroim.2014.10.011. Epub 2014 Nov 3. J Neuroimmunol. 2014. PMID: 25468273 Review.
-
[Progressive multifocal leukoencephalopathy as a complication of natalizumab therapy].Duodecim. 2013;129(7):765-70. Duodecim. 2013. PMID: 23720945 Finnish.
LinkOut - more resources
Full Text Sources
